BR112016012435A8 - vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2 - Google Patents

vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2

Info

Publication number
BR112016012435A8
BR112016012435A8 BR112016012435A BR112016012435A BR112016012435A8 BR 112016012435 A8 BR112016012435 A8 BR 112016012435A8 BR 112016012435 A BR112016012435 A BR 112016012435A BR 112016012435 A BR112016012435 A BR 112016012435A BR 112016012435 A8 BR112016012435 A8 BR 112016012435A8
Authority
BR
Brazil
Prior art keywords
vaccine
porcine circovirus
recombinantly expressed
orf2 protein
circovirus type
Prior art date
Application number
BR112016012435A
Other languages
English (en)
Other versions
BR112016012435A2 (pt
Inventor
Hendrik Witvliet Maarten
Sno Melanie
Fachinger Vicky
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49680926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016012435(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112016012435A2 publication Critical patent/BR112016012435A2/pt
Publication of BR112016012435A8 publication Critical patent/BR112016012435A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

a presente invenção refere-se a uma vacina compreendendo um imunogênio não replicante do circovírus porcino tipo 2 para o uso no tratamento profilático de um animal que tem anticorpos circulantes direcionados contra o circovírus porcino tipo 2, contra uma infecção com circovírus porcino patogênico tipo 2 por uma administração de dose única da vacina na derme do animal.
BR112016012435A 2013-12-03 2014-12-02 vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2 BR112016012435A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195515 2013-12-03
PCT/EP2014/076224 WO2015082458A1 (en) 2013-12-03 2014-12-02 Vaccine against porcine circo virus type 2

Publications (2)

Publication Number Publication Date
BR112016012435A2 BR112016012435A2 (pt) 2017-08-08
BR112016012435A8 true BR112016012435A8 (pt) 2018-01-30

Family

ID=49680926

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016012435A BR112016012435A8 (pt) 2013-12-03 2014-12-02 vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2

Country Status (13)

Country Link
US (1) US10130698B2 (pt)
EP (1) EP3076996B1 (pt)
JP (1) JP6605469B2 (pt)
KR (1) KR20160093047A (pt)
CN (2) CN105848675A (pt)
BR (1) BR112016012435A8 (pt)
CA (1) CA2931137C (pt)
DK (1) DK3076996T3 (pt)
ES (1) ES2771899T3 (pt)
MX (1) MX369039B (pt)
PL (1) PL3076996T3 (pt)
RU (1) RU2712155C2 (pt)
WO (1) WO2015082458A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3076996T3 (pl) 2013-12-03 2020-05-18 Intervet International B.V. Szczepionka przeciwko cirkowirusowi świń typu 2
RU2018118175A (ru) * 2015-10-22 2019-11-25 Интервет Интернэшнл Б.В. Вакцина для защиты mda-позитивного животного от расстройства, возникающего в результате инфекции, вызванной lawsonia intracellularis
WO2017162720A1 (en) 2016-03-23 2017-09-28 Intervet International B.V. A vaccine for intradermal application against pcv2 and prrs virus infection

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236574A1 (en) 1995-11-30 1997-06-05 Daratech Pty. Ltd. Therapeutic and diagnostic compositions
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
DK1651265T3 (da) 2003-07-24 2008-08-18 Merial Ltd Vaccineformuleringer der omfatter en olie-i-vand-emulsion
BRPI0507017A (pt) 2004-01-22 2007-06-05 Intervet Int Bv ácido nucleico que codifica uma proteìna de lawsonia intracellularis, fragmento de dna, molécula de dna recombinante, carreador recombinante vivo, célula hospedeira, proteìna de lawsonia intracellularis, uso da mesma, vacina para combater as infecções por lawsonia intracellularis, método para preparação da mesma, e, teste de diagnóstico
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
JP5106398B2 (ja) * 2005-09-09 2012-12-26 インターベツト・インターナシヨナル・ベー・ベー Ｐｃｖ−２ワクチン
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
PT2481420T (pt) 2006-12-15 2019-05-31 Boehringer Ingelheim Animal Health Usa Inc Vacina para porcos anti-pcv2 de dose única
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US20090317423A1 (en) 2008-01-23 2009-12-24 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
PL3076996T3 (pl) 2013-12-03 2020-05-18 Intervet International B.V. Szczepionka przeciwko cirkowirusowi świń typu 2
CA2931136C (en) 2013-12-03 2023-03-21 Intervet International B.V. Vaccine against lawsonia intracellularis and porcine circovirus 2

Also Published As

Publication number Publication date
RU2712155C2 (ru) 2020-01-24
DK3076996T3 (en) 2020-03-09
CA2931137A1 (en) 2015-06-11
JP2017501984A (ja) 2017-01-19
ES2771899T3 (es) 2020-07-07
BR112016012435A2 (pt) 2017-08-08
US20170157236A1 (en) 2017-06-08
EP3076996B1 (en) 2020-01-15
JP6605469B2 (ja) 2019-11-13
PL3076996T3 (pl) 2020-05-18
CA2931137C (en) 2023-03-14
MX2016007224A (es) 2016-07-21
CN105848675A (zh) 2016-08-10
US10130698B2 (en) 2018-11-20
EP3076996A1 (en) 2016-10-12
CN110354258A (zh) 2019-10-22
MX369039B (es) 2019-10-25
KR20160093047A (ko) 2016-08-05
WO2015082458A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
BR112018016755A2 (pt) vacina contra o vírus da zica
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112012023046A2 (pt) vacinas de vírus de febre aftosa recombinantes e seus respectivos usos
CL2018000963A1 (es) Cosmética que tiene bacterias probióticas
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112017010341A2 (pt) composição cosmética compreendendo um organossilano, um surfactante catiônico e um polímero catiônico tendo densidade de carga maior do que ou igual a 4 meq/g
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
TR201911232T4 (tr) Otoimmünite gelişimine yönelik coriolus versicolorun ekstraktını içeren topikal bileşimler.
UY32208A (es) Uso de antigeno de mycoplasma bovis
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112015004515A2 (pt) composição imunogênica
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
PH12016500946A1 (en) Composition for preventing and curing mycoplasma infection
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112015017903A2 (pt) vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]